Relatlimab Archives - Medical Conferences

NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer

Presented By

Dr Myriam Chalabi, Netherlands Cancer Institute, the Netherlands; Dr Peter de Gooyer, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:00

High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC

Presented By

Dr Iris Nederlof, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, BELLINI

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:35

Relatlimab addition benefits only a subgroup of metastatic NSCLC

Presented By

Prof. Nicolas Girard, Institut Curie, France

Trial

Phase 2, RELATIVITY-104

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:11

Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer

Presented By

Dr Yara Verschoor, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE-3

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 16:04

Novel dual checkpoint blockade improves progression-free survival in melanoma

Presented By

Dr Evan Lipson, Johns Hopkins University, MD, USA

Trial

Phase 3, RELATIVITY-047

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:14

Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma

Presented By

Dr Rodabe Amaria , MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 12:16